Huahai pharmaceutical: the net profit in the first quarter is expected to decrease by 41% - 50% year-on-year
Huahai pharmaceutical announced that in the first quarter of 2022, the company is expected to realize a net profit attributable to the parent company of 127-150 million yuan, a year-on-year decrease of about 41% - 50%.
This text is a result of machine translation.
Related companies：
In-depth
Consumer Discretionary
Amazon Global Selling: A Decade of Growth in a Vast Market
Dec 17, 2024 05:43 PM
Briefing Oct 20, 2023 06:03 PM
· Technology
China’s OpenAI Challenger Zhipu AI Secures Over CNY 2.5 Billion to Step Further on Large-Scale Model
Jan 30, 2024 07:59 PM
Dec 11, 2023 08:49 PM
Jan 05, 2023 07:33 PM
Nov 16, 2022 05:19 PM
Consumer Staples · Analysis
The First Move of the U.S. Postal Service on Cross-Border E-commerce After Trump
"For many high-margin products, even with a 100% tariff, the cost of manufacturing in China is still far lower than local production. Therefore, from a business perspective, high-margin products will become a more prominent focus in cross-border trade. Companies should adjust their strategies to adapt to the new market environment." — Founder of a cross-border brand, interviewed by EqualOcean.
Feb 21, 2025 08:19 PM
Briefing Aug 26, 2021 06:31 PM
· Healthcare
Huahai pharmaceutical: the net profit in the first half of the year was 516 million yuan, a year-on-year decrease of 10.84%
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
The First Move of the U.S. Postal Service on Cross-Border E-commerce After Trump
Feb 21, 2025 08:19 PM
Insight
In-depth
Insight
In-depth
Insight
In-depth
Automotive · Analysis
Shanghai and Shenzhen: The Dual-City Landscape and Corporate Power
Jan 09, 2025 03:35 PM